FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376115191> ?p ?o ?g. }

• W4376115191 abstract "The failure of novel therapies effective in preclinical animal models largely reflects the fact that current models do not really mimic the pathological/therapeutic features of glioblastoma (GBM), in which the most effective temozolomide chemoradiotherapy (RT/TMZ) regimen can only slightly extend survival. How to improve RT/TMZ efficacy remains a major challenge in clinic.Syngeneic G422TN-GBM model mice were subject to RT/TMZ, surgery, piperlongumine (PL), αPD1, glutathione. Metabolomics or transcriptomics data from G422TN-GBM and human GBM were used for gene enrichment analysis and estimation of ROS generation/scavenging balance, oxidative stress damage, inflammation and immune cell infiltration. Overall survival, bioluminescent imaging, immunohistochemistry, and immunofluorescence staining were used to examine therapeutic efficacy and mechanisms of action.Here we identified that glutathione metabolism was most significantly altered in metabolomics analysis upon RT/TMZ therapies in a truly refractory and reliable mouse triple-negative GBM (G422TN) preclinical model. Consistently, ROS generators/scavengers were highly dysregulated in both G422TN-tumor and human GBM. The ROS-inducer PL synergized surgery/TMZ, surgery/RT/TMZ or RT/TMZ to achieve long-term survival (LTS) in G422TN-mice, but only one LTS-mouse from RT/TMZ/PL therapy passed the rechallenging phase (immune cure). Furthermore, the immunotherapy of RT/TMZ/PL plus anti-PD-1 antibody (αPD1) doubled LTS (50%) and immune-cured (25%) mice. Glutathione completely abolished PL-synergistic effects. Mechanistically, ROS reduction was associated with RT/TMZ-resistance. PL restored ROS level (mainly via reversing Duox2/Gpx2), activated oxidative stress/inflammation/immune responses signature genes, reduced cancer cell proliferation/invasion, increased apoptosis and CD3+/CD4+/CD8+ T-lymphocytes in G422TN-tumor on the basis of RT/TMZ regimen.Our findings demonstrate that PL reverses RT/TMZ-reduced ROS and synergistically resets tumor microenvironment to cure GBM. RT/TMZ/PL or RT/TMZ/PL/αPD1 exacts effective immune cure in refractory GBM, deserving a priority for clinical trials." @default.
• W4376115191 created "2023-05-12" @default.
• W4376115191 creator A5001796484 @default.
• W4376115191 creator A5003198921 @default.
• W4376115191 creator A5004448432 @default.
• W4376115191 creator A5013935011 @default.
• W4376115191 creator A5014182741 @default.
• W4376115191 creator A5021852513 @default.
• W4376115191 creator A5028870837 @default.
• W4376115191 creator A5032051637 @default.
• W4376115191 creator A5032789956 @default.
• W4376115191 creator A5080306619 @default.
• W4376115191 creator A5082823142 @default.
• W4376115191 creator A5083205249 @default.
• W4376115191 creator A5085996454 @default.
• W4376115191 creator A5089851953 @default.
• W4376115191 creator A5091554768 @default.
• W4376115191 date "2023-05-10" @default.
• W4376115191 modified "2023-10-16" @default.
• W4376115191 title "Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8+-T cell immunity" @default.
• W4376115191 cites W1990541692 @default.
• W4376115191 cites W1999574084 @default.
• W4376115191 cites W2035618305 @default.
• W4376115191 cites W2052121695 @default.
• W4376115191 cites W2090548255 @default.
• W4376115191 cites W2094524631 @default.
• W4376115191 cites W2096287682 @default.
• W4376115191 cites W2123879591 @default.
• W4376115191 cites W2124199305 @default.
• W4376115191 cites W2127383724 @default.
• W4376115191 cites W2152283027 @default.
• W4376115191 cites W2158681922 @default.
• W4376115191 cites W2165871546 @default.
• W4376115191 cites W2169456326 @default.
• W4376115191 cites W2179438025 @default.
• W4376115191 cites W2310046094 @default.
• W4376115191 cites W2366536035 @default.
• W4376115191 cites W2559588208 @default.
• W4376115191 cites W2765822435 @default.
• W4376115191 cites W2794346955 @default.
• W4376115191 cites W2890296921 @default.
• W4376115191 cites W2901265038 @default.
• W4376115191 cites W2915507494 @default.
• W4376115191 cites W2923127875 @default.
• W4376115191 cites W2946645851 @default.
• W4376115191 cites W2954288760 @default.
• W4376115191 cites W3015283817 @default.
• W4376115191 cites W3015623817 @default.
• W4376115191 cites W3026551532 @default.
• W4376115191 cites W3036247540 @default.
• W4376115191 cites W3041426930 @default.
• W4376115191 cites W3047463220 @default.
• W4376115191 cites W3048894137 @default.
• W4376115191 cites W3049387264 @default.
• W4376115191 cites W3092445835 @default.
• W4376115191 cites W3094561708 @default.
• W4376115191 cites W3104238489 @default.
• W4376115191 cites W3150063851 @default.
• W4376115191 cites W3156308715 @default.
• W4376115191 cites W3171277491 @default.
• W4376115191 cites W3171365255 @default.
• W4376115191 cites W3173215659 @default.
• W4376115191 cites W3173810810 @default.
• W4376115191 cites W3176059815 @default.
• W4376115191 cites W3198675921 @default.
• W4376115191 cites W4211105004 @default.
• W4376115191 cites W4212835999 @default.
• W4376115191 cites W4283265140 @default.
• W4376115191 cites W4285006009 @default.
• W4376115191 doi "https://doi.org/10.1186/s13046-023-02686-1" @default.
• W4376115191 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37161450" @default.
• W4376115191 hasPublicationYear "2023" @default.
• W4376115191 type Work @default.
• W4376115191 citedByCount "0" @default.
• W4376115191 crossrefType "journal-article" @default.
• W4376115191 hasAuthorship W4376115191A5001796484 @default.
• W4376115191 hasAuthorship W4376115191A5003198921 @default.
• W4376115191 hasAuthorship W4376115191A5004448432 @default.
• W4376115191 hasAuthorship W4376115191A5013935011 @default.
• W4376115191 hasAuthorship W4376115191A5014182741 @default.
• W4376115191 hasAuthorship W4376115191A5021852513 @default.
• W4376115191 hasAuthorship W4376115191A5028870837 @default.
• W4376115191 hasAuthorship W4376115191A5032051637 @default.
• W4376115191 hasAuthorship W4376115191A5032789956 @default.
• W4376115191 hasAuthorship W4376115191A5080306619 @default.
• W4376115191 hasAuthorship W4376115191A5082823142 @default.
• W4376115191 hasAuthorship W4376115191A5083205249 @default.
• W4376115191 hasAuthorship W4376115191A5085996454 @default.
• W4376115191 hasAuthorship W4376115191A5089851953 @default.
• W4376115191 hasAuthorship W4376115191A5091554768 @default.
• W4376115191 hasBestOaLocation W43761151911 @default.
• W4376115191 hasConcept C121608353 @default.
• W4376115191 hasConcept C126322002 @default.
• W4376115191 hasConcept C167672396 @default.
• W4376115191 hasConcept C181199279 @default.
• W4376115191 hasConcept C203014093 @default.
• W4376115191 hasConcept C2776151105 @default.
• W4376115191 hasConcept C2776914184 @default.
• W4376115191 hasConcept C2777389519 @default.
• W4376115191 hasConcept C2778227246 @default.

• next